Clinical Trial Update: Effectiveness of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating CRD-4730 in people with catecholaminergic polymorphic ventricular tachycardia was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Catecholaminergic Polymorphic Ventricular Tachycardia
• Congenital Heart Defect
• Congenital Heart Disease
• Ventricular Tachycardia

Drugs mentioned

• CRD-4730

Snippet

Sponsor: Cardurion Pharmaceuticals, Inc. | Conditions: CPVT1, Heart Defects, Congenital | Phase 2 | Status: TERMINATED